Warfarin Sensitivity Testing: Medco/Mayo Study Results Due Early 2010
Executive Summary
Medco is planning to release an observational study in early 2010 on the benefits of pharmacogenomic testing in warfarin dosing. It hopes the results will increase payer acceptance of the approach to treatment
You may also be interested in...
Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011
Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Data suggesting some link between CYP2C9 or VKORC1 gene mutations and a patient's likelihood of fatal excessive bleeding in response to the drug are enough for a coverage-with-evidence-development policy, where beneficiaries enrolled in qualifying trials are covered.